- Home
- PETZ vs MBRX Comparison
PETZ vs MBRX Comparison
Compare PETZ & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | MBRX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 13.1M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PETZ | MBRX |
|---|---|---|
| Price | $1.42 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 712.8K | 259.3K |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $0.25 |
| 52 Week High | $1.68 | $7.98 |
Technical Indicators
Market Signals| Indicator | PETZ | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 80.07 | 51.11 |
| Support Level | $0.98 | $2.24 |
| Resistance Level | $1.68 | $2.64 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 71.43 | 28.13 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc currently focus on commercial real estate management. The company has determined that it has only one operating segment which is commercial real estate leasing operations. The company has presence in China and United States of which majority of revenue comes from China.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.